Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC 50 of 0.7 nM. Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (T max ¼ 1 h; T 1/2 ¼ 1.2 h), although erectile effects have been observed after 7 h. In humans, vardenafil is rapidly absorbed (T max E40 min) and more slowly metabolized (T 1/2 E4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil). Although the consumption of high-fat meals does not affect the drug's relative bioavailability, it retards intestinal absorption. Coadministration of CYP3A4 inhibitors such as ritonavir can affect hepatic metabolism. M1, an active metabolite of vardenafil, is a four-fold-less potent inhibitor of PDE5 than its parent compound, contributing approximately 7% to vardenafil's overall efficacy. The side effects of all selective PDE5 inhibitors commonly include vasodilation, small reductions in blood pressure, headache, and nasal congestion.
Introduction
As mentioned previously, vardenafil exhibits high potency in inhibiting PDE5, with an IC 50 of 0.7 nM. Vardenafil increases intracellular cGMP in the presence of sodium nitroprusside, an NO donor, in both rabbit and human cavernosal tissue. In a direct comparison with sildenafil, vardenafil was proven effective at lower concentrations. 1, 2, 3 Also, vardenafil significantly potentiated both acetylcholine (Ach)-induced and transmural electrical stimulation-induced relaxation of trabecular smooth muscle.
As shown in a conscious rabbit model, the in vitro efficacy of vardenafil has translated to similar efficacy in vivo. Vardenafil potentiated erectile responses to intravenous sodium nitroprusside in conscious rabbits in a dose-dependent manner at doses of 0.1-3 mg/kg. 1, 3 The minimum dose required for a significant erectile effect was determined to be 0.1 mg/kg. Vardenafil also demonstrated effectiveness in an anesthetized rabbit model with pelvic nerve stimulation 2 and in a rat model, displaying greater efficacy on erectile response than sildenafil at comparable doses. 4 Efficacy in vivo not only depends on the potency and the selectivity of a particular PDE5 inhibitor, but also on its pharmacokinetic (PK) properties. They can be characterized by its absorption, distribution, metabolism, and excretion. In general, plasma concentrations of a compound correlate with its efficacy. T max , the time to achieve maximal plasma concentration (C max ), often corresponds to the maximal pharmacodynamic effects of a given pharmacologic agent.
In rabbits, oral vardenafil was eliminated from the plasma at a half-life (T 1/2 ) of approximately 1.2 h, more rapidly than the T 1/2 of 4-5 hours observed in humans. In this model, the vardenafil plasma concentration (T max ¼ 1 h) determined its initial efficacy in enhancing NO-induced erections. However, significant erectile responses persisted even after 7 h (T 1/2 Â 4) when plasma concentrations had declined to 2.5%. This implies that in humans, vardenafil with a T max of approximately 40 min could remain efficacious beyond one T 1/2 . Four active metabolites of vardenafil have been identified. The most prominent metabolite, M1, is vardenafil with its ethyl group removed at the piperazine ring. M1 is an effective PDE5 inhibitor, but with a potency four times less than that of its parent compound. The metabolite's contribution to the overall efficacy of vardenafil has been estimated at approximately 7% ( Table 2) .
The pharmacodynamics and pharmacokinetics of a single oral dose of vardenafil, 10 mg or 20 mg, were studied in 21 patients with erectile dysfunction (ED) in a RigiScan study. 6 Compared to placebo, vardenafil 10 mg led to a mean increase of 24.4 min in the duration of 460% penile rigidity at the base, and of 24.8 min at the tip. For the 20 mg dose, increases in duration of 460% penile rigidity were 37.2 min at the base and 28.7 min at the tip. Plasma levels rose rapidly after oral administration. Median T max was 0.9 h for the 10 mg dose and 0.7 h for the 20 mg dose.
Mean C max was 9.1 and 20.9 mg/l, respectively. The average terminal plasma half-life (T 1/2 ) was 4.2 h for the 10 mg dose and 3.9 h for the 20 mg dose ( Table 2 ). The area under the curve (AUC), normalized for both dose and body weight, was proportional to dose.
Vardenafil was well tolerated. Its administration was associated with a small reduction in blood pressure and a minor compensatory increase in heart rate at parameters not deemed to be clinically relevant. As PDE5 is expressed in vascular smooth muscle cells, vasodilation has been recognized as a potential and mechanism-related side effect of PDE5 inhibitor therapy. The related adverse events of vasodilatation, like cutaneous flushing, headache, nasal congestion, and rhinitis, have been reported with vardenafil use, but it is not yet clear whether headache is due to vasodilation and increased blood flow. 7 However, at standard doses applied to the treatment of ED, these effects have not been determined to produce clinically significant changes. 5 Nitrates and nitrate donor compounds release NO, which stimulates guanylyl cyclase and by doing so enhances the synthesis of cGMP. Consequently, this class of coronary vasodilators is expected to amplify the pharmacodynamic effects of PDE5 inhibition in all tissues and cells that express PDE5. This includes the risk of precipitous hypotension. Therefore, concomitant use of nitrate-containing preparations is contraindicated with PDE5 inhibitor therapy. Although PDE5 is expressed to some extent in human platelets, sildenafil alone exerts no direct effect on platelet function, but in vitro potentiates the antiaggregatory effects of nitric oxide donors. [8] [9] PDE5 is expressed not only in vascular tissue but also in the esophagus and in smooth muscle cells of the intestine. Mechanisms dependent on nitric oxide-cGMP regulate the motility of the esophagus and pylorus. Consequently, dyspepsia and other digestive system disorders have been identified as mechanism-related side effects of PDE5 inhibitor therapy.
As high concentrations of PDE5 are found in various regions of the brain, effects on cognitive and neurologic function have also been associated with PDE5 inhibitors. Growing experimental evidence in various animal models suggests that orally delivered sildenafil or vardenafil improved object recognition memory in rats. 10 When administered before or immediately following training, sildenafil facilitated retention performance of a one-trial step-through inhibitor avoidance task in both male and female mice. 11 Sildenafil may affect retention by altering mechanisms involved in memory storage, possibly through the nitric oxide-guanylyl cyclase-cGMP 
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system. 10 As yet, the effect of PDE5 inhibitors on cognition in humans has not been determined. In a double-blind study of central side effects of sildenafil on attention and memory functions in young male subjects, the drug did not overtly affect behavioral patterns. 12 However, auditory eventrelated brain potentials indicated an enhanced ability to focus attention and to select relevant target stimuli.
The nitric oxide-cGMP pathway is thought to be involved in nociception, and evidence exists that PDE inhibitors can modulate the process of pain perception. Nitric oxide substantially influences the resting activity of dorsal-horn neurons. In rats, blockade of nitric oxide synthesis increased the frequency of background activity of high-threshold mechanosensitive neurons and resulted in activity among 80% of previously inactive neurons. 13 Inhibition of NO synthesis did not significantly impact the background activity of non-nociceptive neurons.
In the formalin test in rats, sildenafil enhanced the antinociceptive effect of diclofenac and produced an antinociceptive effect itself during the latter phase of the test.
14 Furthermore, nitric oxide levels are known to increase in response to peripheral nerve injury. While headache is one of the most common side effects of sildenafil therapy, this drugrelated adverse event can more likely be attributed to vasodilation than to elevated levels of NO. 15, 16, 17 Many uncertainties persist with respect to the interrelationships of pain, cGMP, and the physiologic mechanisms of PDE inhibition. 2. What novel therapies might be developed to treat ED in patients suffering from spinal cord injury? Should pharmaceutical research be devoted to the modulation of the sensory spinal nociceptor system by PDE5 inhibitors? The NO-dependent increase of intracellular cGMP by PDE5 inhibition has been shown to be an effective mechanism in the treatment of ED. Patients suffering from spinal cord injury lack the centrally mediated stimulation of erectile nerves, which normally leads to a release of NO and subsequently to an increased synthesis of cGMP. That might explain the lower efficacy of PDE5 inhibitors in this group of patients. Direct, NO-independent stimulation of soluble guanylyl cyclase (sGC) should also lead to elevated cGMP levels in tissues and could be an attractive alternative therapeutic option for the treatment of ED in these patients. The use of PDE5 inhibitors, which are able to chemically release NO, may be a further option.
Important concepts
Another NO-independent treatment option could be the inhibition of roh-kinase, which has been shown to be effective in relaxation of penile tissue. 19 The role of cGMP in spinal nociceptor transmision is currently only poorly understood. Therefore, the possibility of the modulation of this neuronal network by PDE5 inhibitors is highly speculative and needs a lot of basic research.
